New cell therapy tested for Tough-to-Treat multiple sclerosis

NCT ID NCT06617793

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a single dose of an experimental cell therapy called YTB323 in about 28 adults with relapsing multiple sclerosis. The goal is to see if this treatment is safe and can help control the disease in patients whose current high-efficacy medications are no longer working well enough. Participants will be monitored for 2 years in the main study, with additional long-term follow-up for up to 15 years total.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site
RECRUITING

Montpellier, 34090, France
Novartis Investigative Site
RECRUITING

Nancy, 54035, France
Novartis Investigative Site
RECRUITING

Rennes, 35033, France
Novartis Investigative Site
RECRUITING

Bochum, 44791, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Mainz, 55131, Germany
Novartis Investigative Site
RECRUITING

Ulm, 89081, Germany
Novartis Investigative Site
RECRUITING

Genova, GE, 16132, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20132, Italy
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Córdoba, 14004, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28034, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain
Novartis Investigative Site
RECRUITING

Bern, 3010, Switzerland
Novartis Investigative Site
RECRUITING

Lausanne, 1011, Switzerland
Novartis Investigative Site
RECRUITING

Zurich, 8091, Switzerland

Conditions

Explore the condition pages connected to this study.

RELAPSING MULTIPLE SCLEROSIS